Aptevo Therapeutics Current Ratio 2014-2022 | APVO
Aptevo Therapeutics current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Aptevo Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$0.03B |
$0.01B |
3.16 |
| 2022-06-30 |
$0.03B |
$0.01B |
4.48 |
| 2022-03-31 |
$0.04B |
$0.02B |
1.75 |
| 2021-12-31 |
$0.05B |
$0.04B |
1.51 |
| 2021-09-30 |
$0.06B |
$0.03B |
1.82 |
| 2021-06-30 |
$0.07B |
$0.03B |
2.13 |
| 2021-03-31 |
$0.06B |
$0.03B |
2.14 |
| 2020-12-31 |
$0.05B |
$0.02B |
3.25 |
| 2020-09-30 |
$0.03B |
$0.01B |
4.13 |
| 2020-06-30 |
$0.01B |
$0.01B |
1.50 |
| 2020-03-31 |
$0.02B |
$0.01B |
2.12 |
| 2019-12-31 |
$0.03B |
$0.04B |
0.78 |
| 2019-09-30 |
$0.04B |
$0.04B |
0.99 |
| 2019-06-30 |
$0.04B |
$0.02B |
2.63 |
| 2019-03-31 |
$0.06B |
$0.02B |
3.15 |
| 2018-12-31 |
$0.05B |
$0.02B |
2.77 |
| 2018-09-30 |
$0.06B |
$0.02B |
3.91 |
| 2018-06-30 |
$0.07B |
$0.02B |
3.66 |
| 2018-03-31 |
$0.08B |
$0.02B |
4.47 |
| 2017-12-31 |
$0.10B |
$0.02B |
5.14 |
| 2017-09-30 |
$0.12B |
$0.02B |
7.76 |
| 2017-06-30 |
$0.07B |
$0.01B |
5.66 |
| 2017-03-31 |
$0.08B |
$0.01B |
5.35 |
| 2016-12-31 |
$0.07B |
$0.02B |
3.65 |
| 2016-09-30 |
$0.08B |
$0.02B |
5.21 |
| 2016-06-30 |
$0.04B |
$0.02B |
2.34 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.00B |
|
0.00 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.04B |
$0.02B |
2.10 |
| 2013-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.012B |
$0.012B |
|
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
|
